Unsere Publikationen

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Link
https://doi.org/10.1016/s1474-4422(17)30007-8
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.
Verlag
Lancet Neurol. 2017 Apr;16(4):271-281.
Zum Eintrag

Multiple sclerosis in the real world: A systematic review of fingolimod as a case study

Link
https://doi.org/10.1016/j.autrev.2017.02.007
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
Ziemssen T, Medin J, Couto CA, Mitchell CR.
Verlag
Autoimmun Rev 2017;16(4):355-376.
Zum Eintrag

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

Link
https://doi.org/10.1371/journal.pone.0173353
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T.
Verlag
PLoS ONE 2017;12(5).
Zum Eintrag

Treatment optimization in multiple sclerosis: how do we apply emerging evidence?

Link
https://doi.org/10.1080/1744666x.2017.1292135
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
Ziemssen T, Thomas K.
Verlag
Expert Rev Clin Immunol 2017;13(6):509-511.
Zum Eintrag

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

Link
https://doi.org/10.1186/s12974-017-0945-z
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.
Verlag
J Neuroinflammation. 2017 Aug 31;14(1):172.
Zum Eintrag

To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question

Link
https://doi.org/10.1080/14737175.2017.1340831
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
D'Amico E, Ziemssen T, Cottone S.
Verlag
Expert Rev Neurother 2017;17(9):847-849.
Zum Eintrag

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: An update on the clinical trial evidence and data from the real world

Link
https://doi.org/10.1177/1756285617722706
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
Ziemssen T, Thomas K.
Verlag
Ther Adv Neurol Disord 2017;10(10):343-359.
Zum Eintrag

“Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis” Multiple Sclerosis and Related Disorders 2017

Link
https://doi.org/10.1016/j.msard.2017.07.019
Tags
Multiple SkleroseMS Behandlung
Jahr
2017
Autoren
Thomas K, Ziemssen T.
Verlag
Mult Scler Relat Disord 2017;17:177-178.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-